M
Mavacamten
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
No
Post-marketing information
Patient Alert Card
Patient Medication Guide
Physician Educational Material
Subsidy Information and Financing Scheme
Medical Assistance Fund
Active ingredient: Mavacamten
General information
Subsidy Information and Financing Scheme
[MAF] Mavacamten Capsule 2.5 mg, 5 mg, 10 mg, 15 mg
Treatment of obstructive hypertrophic cardiomyopathy in patients with New York Heart Association (NYHA) class II-III, peak left ventricular outflow tract (LVOT) gradient ≥50 mmHg (at rest or with provocation), and left ventricular ejection fraction (LVEF) ≥55%.
The patient must have had inadequate response to prior trials of (i) a beta-blocker (BB) and (ii) a non-dihydropyridine calcium channel blocker (CCB), unless these are contraindicated or not tolerated.
Mavacamten must be used as an add-on to optimised standard care including a BB and/or a CCB, unless contraindicated or not tolerated.
For continuation of treatment, the patient must have demonstrated a response after receiving the optimal dose of mavacamten for at least 4-6 months, defined as an improvement in at least one of the following: (i) NYHA class, (ii) exercise capacity, or (iii) peak LVOT gradient.
Drug Guidance for Subsidy
04/06/2025 Mavacamten for treating obstructive hypertrophic cardiomyopathy
The Ministry of Health’s Drug Advisory Committee has recommended:
Mavacamten 2.5 mg, 5 mg, 10 mg and 15 mg capsules for treating obstructive hypertrophic cardiomyopathy, in line with the following criteria:
Patients must have New York Heart Association (NYHA) class II to III, peak left ventricular outflow tract (LVOT) gradient ≥50 mmHg (at rest or with provocation), and left ventricular ejection fraction ≥55%; and
Patients must have had an inadequate response to prior trials of (i) a beta-blocker (BB) and (ii) a non-dihydropyridine calcium channel blocker (CCB), unless these are contraindicated or not tolerated; and
Mavacamten must be used as an add-on to optimised standard care including a BB and/or a CCB, unless contraindicated or not tolerated.
For continuation of treatment, the patient must have demonstrated a response after receiving the optimal dose of mavacamten for at least 4-6 months, defined as an improvement in at least one of the following: (i) NYHA class, (ii) exercise capacity, or (iii) peak LVOT gradient.
Funding status
[R] Mavacamten 2.5 mg, 5 mg, 10 mg and 15 mg capsules are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 August 2025.
Post Marketing Information
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Capsule 2.5 mg |
|
Capsule 5 mg |
|
Capsule 10 mg |
|
Capsule 15 mg |
|
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |
Oral
* Clinical information is available for this product.